France: Cross-Company Cooperation Joint Efforts for Development of Microbiome-Based Diagnostics

Bioaster announced the initiation of a collaborative program with Bio-Rad Laboratories and Genetic Analysis aimed at evaluating microbial dysbiosis signatures in the field of metabolic disorders.

Lyon/France — This project is a unique opportunity to capitalize on the deep and 16S-targeted sequencing technologies and advanced pipelines of data analysis for highlighting new gut microbiome biomarkers of medical added value, the French company announced.

Endocrine and metabolic diseases are among the most common contemporary human afflictions in western countries and particularly in the United States. The high prevalence and incidence of common metabolic disorders such as diabetes and obesity have been confirmed through large population-based studies. Moreover, an increasing number of studies show that deregulation of gut microbiota composition (“dysbiosis”) is associated with onset of metabolic diseases and may impact treatment.

UK: iPSC-Derived Microglia

Axol Bioscience Developed New Stem Cell Type for Treatment of Neurodegenerative Diseases

This original collaboration between Bio-Rad, a provider of life science research and clinical diagnostic products, Genetic Analysis, a Norwegian company renowned in microbiome molecular diagnostics and Bioaster will add an innovative edge of this research program by examining gut microbiota signatures for diagnostics. Genetic Analysis and Bio-Rad previously announced in December 2017 a supply and distribution agreement for Genetic Analysis’s GA-map clinical test for gut dysbiosis.

Ronny Hermansen, CEO of Genetic Analysis, added that more and more links are discovered between the human microbiome and immune status. Therefore, the need for accurate biomarker-based tests would become pressing. Genetic Analysis and Bio-Rad had a strong track record along with considerable experience in developing and bringing innovative diagnostic tools to market, he added.

(ID:45644055)